Corcept Therapeutics (CORT)
NASDAQ: CORT
· Real-Time Price · USD
70.84
0.78 (1.11%)
At close: Jun 16, 2025, 3:59 PM
71.21
0.52%
After-hours: Jun 16, 2025, 05:56 PM EDT
1.11% (1D)
| Bid | 70.5 |
| Market Cap | 7.51B |
| Revenue (ttm) | 685.45M |
| Net Income (ttm) | 132.85M |
| EPS (ttm) | 1.15 |
| PE Ratio (ttm) | 61.6 |
| Forward PE | 26.76 |
| Analyst | Strong Buy |
| Ask | 71.21 |
| Volume | 608,386 |
| Avg. Volume (20D) | 1,689,093 |
| Open | 70.89 |
| Previous Close | 70.06 |
| Day's Range | 69.92 - 71.07 |
| 52-Week Range | 28.04 - 117.33 |
| Beta | 0.18 |
About CORT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CORT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CORT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-7.58%
Corcept Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
1 month ago
-4.33%
Corcept Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, HC Wainwright maintained a Buy rating on the stock but lowered its price target from $150 to $145.
1 month ago · seekingalpha.com
Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call TranscriptCorcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Sean Maduck - President, Endocrino...
1 month ago · seekingalpha.com
Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings MissDespite a Q4 revenue miss, Corcept's 2025 revenue still grew 40% to $675 million, and management provided strong guidance for 2025 and beyond, projecting up to $5 billion in revenue. Corcept's potenti...